Vaxxas secures $20 million for Nanopatch vaccine programs Published on February 11, 2015 by Vaccine News Daily Reports Tweet Biotechnology company Vaxxas said on Monday that it has obtained $20 million in equity funding from new and existing investors. The funds represent the first closing of a Series B venture, with the proceeds being used to advance a series of clinical programs and develop a pipeline of new vaccines for major diseases using the Vaxxas-exclusive Nanopatch technology. “As we have advanced the development of our Nanopatch needle-free vaccination technology, we have seen tremendous opportunities to create our own proprietary pipeline of Nanopatch-based vaccine products, as well as those with partners,” Vaxxas President and CEO David Hoey said. “This funding creates an important inflection point for Vaxxas, as we are now poised to create significantly increased value through our first clinical studies.” The Nanopatch platform activates the immune system by targeting vaccines to abundant immunological cells just below the skin’s surface to help fight influenza, polio, bacterial infections and even cancer. Vaxxas recently acquired funding from the World Health Organization to evaluate the Nanopatch for polio vaccination. “OneVentures is proud to lead this Series B financing, which reflects the tremendous potential of Vaxxas through commercialization of the Nanopatch platform,” Dr. Paul Kelly, board chairman at Vaxxas, Ltd., and managing director at OneVentures, Ltd., said. “The funding positions the company to establish a high-value vaccine product pipeline and initiate clinical programs.” You might also like European agency recommends Sanofi Pasteur’s Humenza More cases of measles reported in suburban Chicago Affinivax, PATH team up to develop pneumococcal vaccine Purdue study reveals Listeria prevalent in retail delis NIAID praises participants of successful rotavirus vaccine study in India How People are Paying Next to Nothing for Must Have UGG Australia Boots (LifeFactopia) Study: Ebola virus can survive in dead body for a week AVI BioPharma gets up to $18M to study swine flu Rise in U.S. measles cases due to vaccination opt outs 83 new avian influenza cases confirmed in China Recommended by
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.25 |
Change
0.740(5.48%) |
Mkt cap ! $301.2M | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.25 | $13.35 | $309.6K | 22.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1150 | $14.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 314 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |